galinpepimut-S

March 14, 2017March 15, 2017

Full Transcript of Interview with Sellas on Galinpepimut-S Vaccine Being Tested for MPM

News

Mesothelioma Research News interviewed Angelos Stergiou, MD, ScD, CEO and vice chairman of the board, and Nicholas Sarlis, MD, PhD, senior vice president and chief medical officer of Sellas Life ... Read more

March 14, 2017March 15, 2017

Sellas Shares Plans for Phase 3 Study of Galinpepimut-S Vaccine in MPM Patients

News

Bermuda-based Sellas Life Sciences Group will conduct a Phase 3 clinical trial to investigate the efficacy and safety of the galinpepimut-S vaccine as a potential treatment for patients with malignant pleural ... Read more

October 21, 2016October 21, 2016

Sellas Life Sciences Names Jonathan Eckard as New Chief Business and Strategy Officer

News

Sellas Life Sciences recently named Jonathan Eckard, PhD, as its chief business and strategy officer. Eckard’s doctorate in toxicology and carcinogenesis is from NYU School of Medicine, where he also earned a master’s ... Read more

September 20, 2016September 20, 2016

FDA Moves Galinpepimut-S, Potential Immunotherapy for Malignant Pleural Mesothelioma, to ‘Fast Track’

News

The U.S. Food and Drug Administration has granted Fast Track designation to SELLAS Life Sciences‘ WT1 cancer vaccine — galinpepimut-S — as a possible treatment of malignant pleural mesothelioma. This action ... Read more

September 16, 2016September 16, 2016

SELLAS Collaborates with NIH to Develop Gene-Monitoring Assay for Cancer Immunotherapies

News

SELLAS Life Sciences has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Heart, Lung and Blood Institute of the National Institutes of Health (NIH). CRADA ... Read more

April 6, 2016April 6, 2016

SELLAS’ WT1 Vaccine for Mesothelioma and Other Cancers Renamed Galinpepimut-S by US Council

News

SELLAS Life Sciences Group announced that its WT1 vaccine, a clinical-stage immunotherapy for a wide range of hematologic cancers and solid tumors, including malignant pleural mesothelioma, has been approved to be named galinpepimut-S by ... Read more